Image Place holder

Jason B. Brayer, MD, PhD


Specialty: Hematology/Oncology
Program: Malignant Hematology

Call 1-888-MOFFITT
(1-888-663-3488)

Call 1-888-MOFFITT
(1-888-663-3488)


Locations: Moffitt Cancer Center
Overview

Cancer Types Treated: Multiple Myeloma-Plasma Cell Tumor

My clinical interests include:• Treatment of plasma cell disorders including MGUS, multiple myeloma, and Waldenstrom’s Macroglobulinemia.• Participation or leadership in clinical trials investigating the development of immunotherapeutic approaches in multiple myeloma (including immunomodulatory agents, vaccine studies, and cellular-based adoptive immunotherapy)

Education & Training

Board Certification:

  • Hematology
  • Internal Medicine
  • Medical Oncology

Fellowship:

  • La Jolla Institute of Allergy & Immunology - Immunology
  • H. Lee Moffitt Cancer Center and Research Institute -
  • H. Lee Moffit Cancer Center and Research Institute - Hematology/Oncology

Residency:

  • University of South Florida - Internal Medicine

Medical School:

  • University of South Florida - MD
Awards
ASCO Young Investigator AwardSponsor: American Society of Clinical Oncology Start Year: 2014 End Year: 2014
Participating Trials

CLINICAL TRIAL 50259
Understanding the Dynamic Composition of Immune Subpopulations in the Course of Multiple Myeloma Disease Progression and Emergence of Drug Resistance
Condition: Multiple Myeloma
Intervention:
Open

CLINICAL TRIAL 19194
A Phase 1 Study of bb21217, an anti-BCMA CAR T Cell Drug Product, in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Not Applicable; bb21217; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19360
Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT): A Phase 2 Trial of Induction, Consolidation and Maintenance in Subjects with High Risk Smoldering Multiple Myeloma (SMM)
Condition: Malignant Hematology
Intervention: CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Lenalidomide (Revlimid); carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19722
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of Bb2121 In Subjects With Relapsed And Refractory Multiple Myeloma And In Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year Of Initial Treatment
Condition: Malignant Hematology
Intervention: bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19962
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+Subjects with Relapsed/Refractory HPV16+ Cancers
Condition: Head & Neck
Intervention: KITE-439; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 19813
A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Efficacy and Safety of BB2121 Versus Standard Triplet Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (Rrmm) (Karmma-3)
Condition: Malignant Hematology
Intervention: Bortezomib; CC-4047 (Pomalidomide); CC-5013 (Lenalidomide); Daratumumab; Dexamethasone; Ixazomib (Ninlaro); Lenalidomide (Revlimid); PS-341 (Bortezomib); Pomalidomide; Velcade (Bortezomib); bb2121; cyclophosphamide; cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
Open

CLINICAL TRIAL 20038
Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Malignant Hematology
Intervention: CB-839; Dexamethasone; carfilzomib (Kyprolis)
Open

CLINICAL TRIAL 19158
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Condition: Malignant Hematology
Intervention: Atezolizumab (Tecentriq)
Open

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Baz R, Naqvi SMH, Lee JH, Brayer J, Hillgruber N, Fridley BL, Shain KH, Sullivan DM, Alsina M. Lenalidomide-based response-adapted therapy for older adults without high risk myeloma. Brit J Haematol. 2019 Mar;184(5):735-743. Pubmedid: 30548250.
  • Sallman DA, Brayer J, Sagatys EM, Lonez C, Breman E, Agaugué S, Verma B, Gilham DE, Lehmann FF, Davila ML. NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 2018 Sep;103(9):e424-e426. Pubmedid: 29703727. Pmcid: PMC6119132.
  • Rose AM, Brayer J. Connecting the Dots: A Case of Myeloid Sarcoma. Am J Med. 2018 Sep;131(9):e357-e359. Pubmedid: 29729239.
  • Zhu G, Brayer J, Padron E, Mulé JJ, Mailloux AW. OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A. 2018 Oct;93(10):982-986. Pubmedid: 30347519. Pmcid: PMC6484443.
  • Lonez C, Verma B, Hendlisz A, Aftimos P, Awada A, Van Den Neste E, Catala G, Machiels JH, Piette F, Brayer JB, Sallman DA, Kerre T, Odunsi K, Davila ML, Gilham DE, Lehmann FF. Study protocol for THINK: a multinational open-label phase I study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumour types. BMJ Open. 2017 Nov;7(11):e017075. Pubmedid: 29133316. Pmcid: PMC5695348.
  • Brayer J, Baz R. The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma. Ther Adv Hematol. 2017 Jul;8(7):209-220. Pubmedid: 28694935. Pmcid: PMC5495505.
  • Brayer J, Lancet JE, Powers J, List A, Balducci L, Komrokji R, Pinilla-Ibarz J. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides. Am J Hematol. 2015 Jul;90(7):602-607. Pubmedid: 25802083. Pmcid: PMC4617516.
  • Dalia S, Brayer J, Horna P, Zhang H, Pinilla-Ibarz J. Transformation to Hodgkin lymphoma in chronic lymphocytic leukemia coexisting with Epstein-Barr viremia. Leuk Lymphoma. 2014 Nov;55(11):2660-2662. Pubmedid: 24528217.
  • Brayer J, Fishman M. Regression of metastatic clear cell kidney cancer with interleukin-2 treatment following nivolumab (anti-PD-1) treatment. J Immunother. 2014 Apr;37(3):187-191. Pubmedid: 24598453.
  • Brayer J, Cheng F, Wang H, Horna P, Vicente-Suarez I, Pinilla-Ibarz J, Sotomayor EM. Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3. Immunol Lett. 2010 Jul;131(2):126-130. Pubmedid: 20346983. Pmcid: PMC2906450.
  • Vicente-Suarez I, Brayer J, Villagra A, Cheng F, Sotomayor EM. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol Lett. 2009 Aug;125(2):114-118. Pubmedid: 19555720. Pmcid: PMC2758552.
  • Horna P, Cuenca A, Cheng F, Brayer J, Wang HW, Borrello I, Levitsky H, Sotomayor EM. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity. Blood. 2006 Apr;107(7):2871-2878. Pubmedid: 16339406. Pmcid: PMC1895389.
  • Ghansah T, Paraiso K, Highfill S, Desponts C, May S, McIntosh J, Wang J, Ninos J, Brayer J, Cheng F, Sotomayor E, Kerr W. Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses. J Immunol. 2004 Dec;173(12):7324-7330. Pubmedid: 15585856.
  • Rodriguez P, Quiceno D, Zabaleta J, Ortiz B, Zea A, Piazuelo M, Delgado A, Correa P, Brayer J, Sotomayor E, Antonia S, Ochoa J, Ochoa A. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004 Aug;64(16):5839-5849. Pubmedid: 15313928.
  • Cheng F, Wang H, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr W, TakedaK, Akira S, Schoenberger S, Yu H, Jove R, Sotomayor E. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003 Sep;19(3):425-436. Pubmedid: 14499117.
  • Cuenca A, Cheng F, Wang H, Brayer J, Horna P, Gu L, Bien H, Borrello I, Levitsky H, Sotomayor E. Extra-lymphatic solid tumor growth is not immunologically ignored and results in early induction of antigen-specific T-cell anergy: dominant role of cross-tolerance to tumor antigens. Cancer Res. 2003 Dec;63(24):9007-9015. Pubmedid: 14695219.